VIENNA, May 21, 2012 /PRNewswire/ --
Austrian BIOCRATES Life Sciences AG, prime developer of state-of-the-art metabolite biomarker panels, is about to launch new editions of two of its well-established research kit products -AbsoluteIDQ® p180 and p150. Originally developed for use with the AB Sciex mass spectrometers, both kits are now available for Waters Xevo® TQ MS systems, greatly increasing sample throughput and accelerating up analytical processes.
AbsoluteIDQ® p180 Kit-Waters Xevo® TQ MS edition
Now also running on the ACQUITY UPLC® system by Waters, the new edition of the AbsoluteIDQ p180 Kit speeds up your research, requiring only 16 hours of measurement time compared with 32 hours for conventional high performance liquid chromatography (HPLC). The Waters UPLC® technology was created especially for scientists who seek a reliable technology that simultaneously improves laboratory productivity, efficiency, and throughput.
Quantifying more than 180 metabolites from key metabolic pathways, the AbsoluteIDQ p180 Kit delivers the widest range of metabolomic information available from a single targeted assay. Analyzed metabolite classes include acylcarnitines, amino acids and biogenic amines, hexose, and sphingo- and glycerophospholipids.
AbsoluteIDQ® p150 Kit-Waters Xevo® TQ MS edition
Also now available for Waters Xevo TQ mass spectrometers is the AbsoluteIDQ p150 Kit, which identifies and quantifies 158 metabolites from 4 compound classes using a FIA-MS/MS method.
Both kits feature the proprietary MetIDQ™ software for the automated calculation of metabolite concentrations, require only small sample volumes of 10 µL, and are suitable for use with a wide range of biological samples.
BIOCRATES Life Sciences AG is a leading biotechnology company focused on biomarker discovery and the development of MS-based standardized metabolomics kits as well as in vitro diagnostics (IVDs). Please visit us at http://www.biocrates.com.
For questions: Michael Leitner, Public Health PR
Tel.: +43-1-602-05-30-92, e-mail: email@example.com
SOURCE Biocrates Life Sciences AG